Literature DB >> 12527580

Treatment of stage IIIA non-small cell lung cancer.

Lary A Robinson1, Henry Wagner, John C Ruckdeschel.   

Abstract

Stage IIIA non-small cell lung cancer represents a relatively heterogeneous group of patients with metastatic disease to the ipsilateral mediastinal (N2) lymph nodes and also includes T3N1 patients. Presentations of disease range from apparently resectable tumors with occult microscopic nodal metastases to unresectable, bulky multistation nodal disease. Controversy abounds as to the optimal treatment of the various stage IIIA subsets, which is fueled by a lack of meaningful, large randomized trials. Multimodality therapy of some type appears to be preferable in stage IIIA patients.

Entities:  

Mesh:

Year:  2003        PMID: 12527580     DOI: 10.1378/chest.123.1_suppl.202s

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  13 in total

Review 1.  [Results of N1 and N2 surgery in non-small cell lung cancer].

Authors:  J Pfannschmidt; J Kollmeier
Journal:  Chirurg       Date:  2019-12       Impact factor: 0.955

2.  [Interdisciplinary treatment of non-small cell lung cancer].

Authors:  J Dunst; C Kugler; D Ukena
Journal:  Internist (Berl)       Date:  2011-02       Impact factor: 0.743

Review 3.  The Latest on Lung Ablation.

Authors:  Peyton Cramer; Bradley B Pua
Journal:  Semin Intervent Radiol       Date:  2022-08-31       Impact factor: 1.780

4.  Phase I study of cisplatin and irinotecan combined with concurrent hyperfractionated accelerated thoracic radiotherapy for locally advanced non-small cell lung carcinoma.

Authors:  Yuichi Takiguchi; Reiko Uruma; Yoshiko Asaka-Amano; Katsushi Kurosu; Yasunori Kasahara; Nobuhiro Tanabe; Koichiro Tatsumi; Takashi Uno; Hisao Itoh; Takayuki Kuriyama
Journal:  Int J Clin Oncol       Date:  2005-12       Impact factor: 3.850

5.  Bevacizumab: the evidence for its clinical potential in the treatment of nonsmall cell lung cancer.

Authors:  Sonya Haslam; Paul Chrisp
Journal:  Core Evid       Date:  2007-03-31

6.  Improving the use of research evidence in guideline development: 10. Integrating values and consumer involvement.

Authors:  Holger J Schünemann; Atle Fretheim; Andrew D Oxman
Journal:  Health Res Policy Syst       Date:  2006-12-05

7.  Supraclavicular lymph node incisional biopsies have no influence on the prognosis of advanced non-small cell lung cancer patients: a retrospective study.

Authors:  Song Dong; Ning Zhao; Wei Deng; Hui-Wen Sun; Fei-Yu Niu; Jin-Ji Yang; Wen-Zhao Zhong; Feng Li; Hong-Hong Yan; Chong-Rui Xu; Qiu-Yi Zhang; Xue-Ning Yang; Ri-Qiang Liao; Qiang Nie; Yi-Long Wu
Journal:  World J Surg Oncol       Date:  2017-01-09       Impact factor: 2.754

8.  MicroRNA-29c functions as a tumor suppressor by targeting VEGFA in lung adenocarcinoma.

Authors:  Lipin Liu; Nan Bi; Lihong Wu; Xiao Ding; Yu Men; Wei Zhou; Lin Li; Weimin Zhang; Susheng Shi; Yongmei Song; Luhua Wang
Journal:  Mol Cancer       Date:  2017-02-28       Impact factor: 27.401

9.  [Survival Analysis of 121 Stage N2-IIIa Non-small Cell Lung Cancer Patients 
Treated with Surgery].

Authors:  Heli Yang; Liang Dai; Pei Li; Luyan Shen; Wanpu Yan; Mengying Fan; Keneng Chen
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2015-08

10.  [Diagnostic Value of Transbronchial Ultrasound-guided Needle Aspiration Biopsy in the Diagnosis of Small Cell Lung Cancer and Non-small Cell Lung Cancer].

Authors:  Xiaogang Tan; Baodong Liu; Ruotian Wang; Yi Zhang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2020-06-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.